Limován

Zopiclone, the active ingredient in Limován, is a cyclopyrrolone (non‑benzodiazepine hypnotic) presented as an oral tablet for oral use. It is indicated for short‑term treatment of insomnia in adults who have difficulty falling or staying asleep.

GNH USA supplies Limován as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zopiclone is a hypnotic agent that acts on the central nervous system to treat sleep disorders.

Insomnia (short‑term): helps initiate and maintain sleep in adults. Sleep onset insomnia: reduces the time needed to fall asleep. Sleep maintenance insomnia: decreases nocturnal awakenings and improves sleep continuity.

Zopiclone may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Bitter or metallic taste. - Dry mouth. - Drowsiness or fatigue during the day. - Headache.

Serious or Rare Side Effects: - Complex sleep behaviours such as sleep‑walking or driving while not fully awake. - Allergic reactions including rash, itching, or swelling. - Severe respiratory depression, especially when combined with other depressants.

Before using Limován, consider the following safety measures.

Avoid abrupt discontinuation: taper under medical supervision to reduce withdrawal risk. Limit alcohol: concurrent use may increase sedation and respiratory depression. Use caution in the elderly: increased sensitivity may lead to falls or confusion. Assess liver function: impaired metabolism can raise drug levels. Store at ambient temperature: keep below 25°C in the original container, protected from moisture and light.

Zopiclone can interact with several other medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Opioids: additive respiratory depression. - Central nervous system depressants (e.g., barbiturates, antihistamines): heightened sedation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increased plasma concentrations.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin): reduced efficacy. - Antidepressants (e.g., fluoxetine): may enhance sedative effect. - Antihypertensives: potential additive hypotensive effect.